Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
(2003) Journal of Clinical Endocrinology & Metabolism n=120 Phase 2 double-blind trial of AOD 9604 5mg daily versus placebo in obese subjects measuring weight loss and lipid changes
NICE guidance supports its use in specific patient populations where other treatments have proven inadequate
A practical middle-ground strategy uses two concentrations: a lower concentration (23mg/ml) for initial titration phases where doses remain below 1mg/kg, and a higher concentration (810mg/ml) for maintenance or high-dose phases
may reduce malondialdehyde, a marker of cell damage in the liver Improve blood sugar regulating hormone resistance: low glutathione levels are associated with less fat burning and higher rates of fat storing - supplementing may improve both Increase mobility in peripheral artery disease patients: when the peripheral arteries become clogged with plaque, glutathione may improve circulation, enabling patients to walk longer distances Reduce Parkinson's disease symptoms: intravenous glutathione may help reduce tremors and muscle rigidity Reduce oxidative damage in children with autism: these children have higher levels of oxidative damage and lower levels of glutathione in their brains
Choose an option Factory-sealed box containing 5 vials of 5mg each
